Filing Flows › Fate Therapeutics (FATE) › Q2 2026 › vs Q1 2026
Fate Therapeutics (FATE) Q2 2026 vs Q1 2026 (quarter over quarter)
Fate Therapeutics's revenue rose $783K (+60%) from $1.3M in Q1 2026 to $2.1M in Q2 2026.
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $2.1M | $1.3M | $783K | +60% |
| Other income, net | $975K | $1.8M | −$812K | -45% |
| Net loss | $30.2M | $31.2M | −$1.1M | -3% |
| Costs & expenses | $33.2M | $34.3M | −$1.1M | -3% |
| Operating costs | $33.2M | $34.3M | −$1.1M | -3% |
| Research & development | $24.4M | $24.7M | −$316K | -1% |
| General & admin | $8.8M | $9.6M | −$767K | -8% |
| Operating cash sources | $30.2M | $31.2M | −$1.1M | -3% |
| Depreciation & amortization | $2.8M | $2.9M | −$138K | -5% |
| Share-based compensation | $3.5M | $3.9M | −$411K | -10% |
| Working capital & other | $461K | −$6.5M | $6.9M | — |
| Cash used in operations | $23.4M | $30.8M | −$7.4M | -24% |
| Net loss absorbed | $30.2M | $31.2M | −$1.1M | -3% |
Questions
How much did Fate Therapeutics's revenue grow quarter over quarter in Q2 2026?
Fate Therapeutics's revenue rose $783K (+60%) from $1.3M in Q1 2026 to $2.1M in Q2 2026.